Zanubrutinib Continues to Provide PFS Benefit Vs Ibrutinib in Relapsed/Refractory CLL/SLL
December 19th 2023Jennifer R. Brown, MD, PhD, discusses the clinical implications of the ALPINE study and highlights a subgroup analysis of acquired mutations in patients with chronic lymphocytic leukemia, demonstrating which mutations were associated with resistance to covalent BTK inhibitors.
Responses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL
December 13th 2023Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
December 11th 2023Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.
MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL
December 10th 2023Ibrutinib plus venetoclax, given at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia.
Pirtobrutinib Demonstrates Durable Efficacy in Covalent BTK Inhibitor–Pretreated CLL/SLL
December 10th 2023Pirtobrutinib continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a covalent BTK inhibitor.
Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL
December 10th 2023Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.